liraglutide Pen Injector [Saxenda]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Corresponding author: Sungrae Kim Division of Endocrine and Metabolism, The Catholic University of Korea, Bucheon St. Mary’s…
Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as…
Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as…
Globally, obesity has reached epidemic proportions and poses an ever increasing burden from a societal and healthpayer…
Liraglutide (Saxenda®; 3 mg dose), a glucagon-like peptide-1 receptor agonist, is indicated as an adjunct to a reduced-calorie…
Despite much advertising to the contrary, there are no dietary supplements that safely and effectively cause weight loss…
This article highlights important prescribing information for some drugs that received FDA approval within the past year. These…